A multi-centre, double-blind, placebo-controlled, randomised, parallel group clinical trial to evaluate efficacy and safety of Actovegin® in diabetic type 2 patients with symptomatic diabetic peripheral polyneuropathy

Registry ID

EUCTR2006-004007-19

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

Nycomed Austria GmbH

Start date

2006-11-15

Last update

2026-08-16

Conditions

• Diabetic Polyneuropathy

Summary

To evaluate efficacy and safety of Actovegin® (Actovegin) versus placebo given as intravenous (i.v.) infusions once daily for 20 days, followed by oral treatment for 140 days in patients with symptomatic diabetic peripheral polyneuropathy.

Locations

• , , Austria

Related clinical trials

• Peripheral Magnetic Stimulation With Balance Training to Decrease Fall Risks in Diabetic Polyneuropathy
• Effect of Vagus Nerve Stimulation on Pain Intensity, Nerve Conduction Studies and Functional Outcomes in Diabetic Peripheral Neuropathy Patients
• Early Percutaneous Transluminal Angioplasty in Diabetic Foot Syndrome (PTA-DFS)
• Combined Effects of Foot-Ankle Therapeutic Exercises and Mindful Walking in Patients With Diabetic Polyneuropathy
• Investigation of Ultrasonographic Measurements of Lower Extremity Nerves in Type 2 Diabetes Patients With Peripheral Polyneuropathy
• Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study

View on source registry